Arcutis Biotherapeutics Q2 EPS $(0.84) Up From $(0.94) YoY
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.84) per share. This is a 10.64 percent increase over losses of $(0.94) per share from the same period last year.
Hycroft Mining CEO Says Mgmt. Currently Transforming Co. Into Larger-Scale Commercial Operation, Started Feasibility Study On Transformative Measure Last Year, Expected To Complete Feasibility Study By End Of 2022
https://www.youtube.com/watch?v=ppvZVPj3Ao8
Related Posts
Comscore Announces Names Jon Carpenter As CFO
Comscore (NASDAQ:SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, today announced the appointment of Jon Carpenter as Chief Financial Officer. Carpenter, who will
Xpel Buys Five Businesses In US, Canada For $20.1M
Xpel Inc (NASDAQ:XPEL) has acquired five businesses in the U.S. and Canada from two sellers for a combined purchase price of…
Scotiabank Maintains Underperform on Essex Property Trust, Lowers Price Target to $211
Scotiabank analyst Nicholas Yulico maintains Essex Property Trust (NYSE:ESS) with a Underperform and lowers the price target from $235 to $211.